NMRA Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Neumora Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.77 |
| 52 Week High | US$21.00 |
| 52 Week Low | US$8.33 |
| Beta | 0 |
| 11 Month Change | -20.37% |
| 3 Month Change | -15.56% |
| 1 Year Change | -19.12% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.88% |
Recent News & Updates
Shareholder Returns
| NMRA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.9% | 2.8% | 2.2% |
| 1Y | -19.1% | 11.8% | 32.6% |
Return vs Industry: NMRA underperformed the US Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: NMRA underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| NMRA volatility | |
|---|---|
| NMRA Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NMRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NMRA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 109 | Henry Gosebruch | www.neumoratx.com |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.
Neumora Therapeutics, Inc. Fundamentals Summary
| NMRA fundamental statistics | |
|---|---|
| Market cap | US$1.56b |
| Earnings (TTM) | -US$293.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs NMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$293.70m |
| Earnings | -US$293.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NMRA perform over the long term?
See historical performance and comparison